Staedtisches Klinikum Braunschweig gGmbH
- Address
- lock Available on a paid plan
Urology Oncology Research
At Staedtisches Klinikum Braunschweig gGmbH, clinical research in urology is centered on neoplasms, especially cancers affecting the prostate and other solid tumors. The studies focus on testing new treatment approaches, checking safety, and improving how well therapies control disease.
- Research on prostate cancer, including high-risk, locally advanced, and recurrent disease
- Studies in Ewing sarcoma aimed at improving event-free survival and treatment outcomes
- Trials in mature aggressive B-cell lymphoma and leukemia in children and adolescents assessing better disease control
Overall, the site supports a focused oncology portfolio that includes evaluating new hormonal therapies, refining local cancer treatment, and improving survival for patients with difficult-to-treat malignancies.
Prostate Cancer Treatment Studies
Several trials at this hospital examine advanced treatment strategies for prostate cancer, with attention to high-risk localized, locally advanced, and recurrent disease. The goal is to improve disease control and long-term outcomes while also assessing safety and effectiveness.
- Testing androgen receptor-targeted therapy for men receiving radiation therapy
- Evaluating treatment options before and after surgery in high-risk disease
- Studying a new local approach for recurrent prostate cancer
These studies explore whether newer hormonal and local therapies can better prevent progression and improve response compared with current standard care.
Ewing Sarcoma and Pediatric Cancer Research
The site also contributes to research in pediatric oncology, with trials for Ewing sarcoma and mature aggressive B-cell lymphoma or leukemia in younger patients. These studies aim to improve survival while reducing treatment-related burden.
- Optimizing therapy for Ewing sarcoma to improve event-free survival
- Assessing whether treatment changes can maintain outcomes in children with limited B-cell non-Hodgkin lymphoma
- Studying immune recovery and effectiveness of added rituximab in advanced pediatric blood cancers
This research focuses on making cancer treatment more effective for children and adolescents, while also examining whether therapy can be simplified without losing benefit.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 1 therapeutic areas and 15 of 21 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1GPOH gGmbH1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Staedtisches Klinikum Braunschweig gGmbH
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (20321) An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer sponsored studies | Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2020 | — |
IMP list
lock Showing 1 of 21 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Apalutamide | 2 | Unknown | 2016-01-27 | 2019-07-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.